← All articles

October 15, 2026

Wegovy Side Effects: 44% Report Nausea; Know When to Get Help

Woman pauses beside Wegovy pen and water

Most people who start Wegovy experience nausea, diarrhea, vomiting, constipation, headache, or fatigue, especially during the first weeks of a new dose. Severe, persistent abdominal pain, yellowing skin or eyes, signs of severe low blood sugar, or swelling and trouble breathing are red flags that need urgent medical attention. Gastrointestinal symptoms are usually dose-related: they tend to peak during dose escalation and often ease once your body adjusts.

TL;DR:

  • Trial rates were 44% for nausea, 30% for diarrhea, 25% for vomiting, and 24% for constipation; median episodes lasted 8, 3, and 2 days, respectively.
  • If symptoms worsen after an increase, ask your prescriber about holding or lowering the dose; slower titration can reduce nausea without reducing weight loss.
  • Gallstones occurred in 1.6% of adults receiving Wegovy injections versus 0.7% on placebo, and rapid or substantial weight loss also raises the risk.
  • People combining Wegovy with insulin or sulfonylureas face higher risk of low blood sugar, so clinicians may recommend closer glucose checks and medication dose adjustments.
  • Tell your anesthesia team before any procedure involving general anesthesia or deep sedation, because Wegovy has been associated with aspiration risk.
Legacymeds
Weight Loss Care With Ongoing Support
Legacy Meds offers personalized GLP-1 weight loss care with continued guidance, helping you explore an approach tailored to your needs.
Explore personalized care

Table of Contents

Common Side Effects and How Often They Happen in Trials

Gastrointestinal symptoms are by far the most frequent complaint among people taking Wegovy, and clinical trial data give a clear picture of just how common they are. In adult weight-management trials, gastrointestinal adverse events were reported in about 73% of people taking Wegovy compared with 47% on placebo, according to DailyMed’s prescribing information. A pooled analysis of the STEP trials found a nearly identical split, 72.9% versus 47.1%, and importantly found that these events were overwhelmingly mild-to-moderate (98.1%) and non-serious (99.5%), according to pooled STEP-trial data.

Nausea affects about 44% of people on Wegovy, making it the single most common side effect reported in clinical trials, according to DailyMed. That figure sits well above the other common gastrointestinal complaints, though several of them still affect a meaningful share of patients.

  • Nausea: reported in roughly 44% of patients, per the WEGOVY prescribing information.
  • Diarrhea: reported in roughly 30% of patients.
  • Vomiting: reported in roughly 25% of patients.
  • Constipation: reported in roughly 24% of patients.

Beyond these four, the FDA approval label lists several other reactions occurring in 5% or more of patients: abdominal pain, a tingling or altered-sensation symptom called dysesthesia, headache, fatigue, dyspepsia (indigestion), dizziness, and nasopharyngitis (common cold-type symptoms). Belching and flatulence also appear in trial reporting, and some patients report hair thinning, though this is reported far less frequently than the gastrointestinal symptoms above.

Severity matters as much as frequency. Most gastrointestinal reactions are mild to moderate, but severe gastrointestinal reactions were reported in 4.1% of Wegovy-treated patients compared with 0.9% on placebo, according to DailyMed. That gap is one reason prescribers build in a slow dose-escalation schedule rather than starting at a full maintenance dose. The trials behind these figures ran for up to 68 weeks in adults being treated for chronic weight management, so the numbers reflect sustained use rather than a short initial reaction window.

Severe gastrointestinal reaction rates compared

It helps to think of these side effects less as universal and more as a spectrum: some people sail through dose increases with mild stomach upset, while others experience a cluster of symptoms that require a slower pace or temporary dose hold. Knowing the baseline rates gives you a reference point for what counts as typical and what might warrant a call to your prescriber.

How Long Side Effects Typically Last During Treatment

Gastrointestinal side effects on Wegovy follow a predictable pattern tied closely to dose escalation. Each time the dose increases, the likelihood of a new or worsened symptom rises temporarily, and the cumulative rate of gastrointestinal adverse events across a treatment course tends to plateau around week 20, according to pooled STEP-trial data. In other words, most of the gastrointestinal burden shows up in the first several months, not evenly spread across a year or more of treatment.

Nausea lasts a median of about 8 days per episode, while diarrhea and vomiting tend to resolve faster, according to Drugs. Reported median durations include:

  • Nausea: median duration of about 8 days per episode.
  • Diarrhea: median duration of about 3 days per episode.
  • Vomiting: median duration of about 2 days per episode.
  • Constipation: duration varies more by individual and dose level, and some trial reporting suggests longer-lasting episodes than the acute symptoms above.

These are episode durations, not a single continuous stretch of illness. A person might experience nausea after one dose increase, feel fine for a while, then have a shorter repeat episode after the next increase. The pattern tends to soften as the body adapts to each new dose level.

The broader reassurance from trial data is that these events are overwhelmingly mild-to-moderate and transient rather than escalating or permanent, according to pooled STEP-trial findings. Only a small share of patients discontinue Wegovy permanently because of gastrointestinal adverse events, and the same analysis found that gastrointestinal symptoms contributed less than one percentage point to the drug’s overall weight-loss effect, meaning the symptoms are a tolerability issue rather than a sign that the medication isn’t working. That distinction is worth remembering if a rough week tempts you to assume the treatment has failed: discomfort and efficacy are not the same signal.

How Long Side Effects Typically Last During Treatment — overview diagram

Serious and Rare Risks Covered in the Prescribing Information

While most people on Wegovy deal only with gastrointestinal discomfort, the prescribing information outlines several rarer but more serious risks that require prompt recognition. These aren’t common, but knowing the warning signs matters because early action changes outcomes.

Acute pancreatitis is one of the more serious warnings on the label. It typically presents as severe, persistent pain in the upper abdomen that may radiate to the back, sometimes with nausea and vomiting that doesn’t follow the usual pattern. Cases have been observed in people taking Wegovy, and the FDA approval label states that the medication should be discontinued if pancreatitis is suspected.

Acute gallbladder disease shows up in trial data at a meaningfully higher rate than placebo. Cholelithiasis, the medical term for gallstones, was reported in about 1.6% of injection-treated adults compared with 0.7% on placebo, according to FDA clinical review materials. Part of this risk is tied to the medication’s mechanism, but rapid or substantial weight loss on its own independently raises the chance of developing gallstones, regardless of how that weight loss is achieved.

Hypoglycemia becomes a bigger concern when Wegovy is combined with insulin or insulin secretagogues (a category of diabetes medications that stimulate insulin release). The prescribing information flags this interaction specifically, and people on these combinations typically need more frequent glucose monitoring along with a possible dose reduction of the insulin or secretagogue.

A few other risks round out the serious-but-less-common category:

  • Acute kidney injury: linked to dehydration from severe vomiting or diarrhea, with cases reported after marketing.
  • Thyroid C-cell tumor signal: observed in rodent studies, with unclear relevance to humans; Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
  • Severe hypersensitivity: including anaphylaxis and angioedema, which involve swelling and breathing difficulty and require emergency treatment.
  • Other label-noted signals: diabetic retinopathy complications in some trial participants, an increase in resting heart rate, and reports related to fractures and appendicitis in trial populations.

None of these risks are common in the way nausea or constipation are common, but they carry higher stakes, which is why the label singles them out and why your prescriber will ask about personal and family medical history before starting treatment.

Practical Ways to Manage Nausea, Vomiting, and Other Symptoms

Tolerability strategies exist because the evidence shows they work, not just because they sound reasonable. The single most supported approach is slower, more flexible dose titration: clinical-experience analyses have found that a gentler escalation pace meaningfully reduces nausea and discontinuation rates without cutting into weight-loss results, according to research on GLP-1 tolerability management. If a dose increase hits hard, holding at the current level for a few extra weeks before moving up is a legitimate, evidence-backed option rather than a failure of the treatment plan.

Several day-to-day habits also make a real difference:

  1. Eat smaller, lower-fat meals, since fatty foods are a common trigger for nausea and delayed stomach emptying.
  2. Separate liquids from solids at meals rather than drinking large amounts of fluid alongside food.
  3. Avoid lying down right after eating, since reflux and nausea tend to worsen in a flat position.
  4. Time your weekly dose for a day when you can rest if symptoms tend to cluster soon afterward.
  5. Add fiber and fluids gradually if constipation is the main issue, since a sudden change can backfire.

Pro Tip: Keep a simple log of symptom timing relative to your dose day: a pattern that repeats after each increase gives your prescriber exactly the information needed to adjust your schedule.

For symptoms that don’t resolve with diet and timing changes, short-term symptomatic medications such as over-the-counter antiemetics, antidiarrheals, or stool softeners can help, though these are worth discussing with your prescriber first rather than combining on your own. Hydration matters more than it might seem: persistent vomiting or diarrhea can lead to meaningful fluid and electrolyte loss, and electrolyte replacement drinks are a reasonable first step. If you’re unable to keep fluids down, feel lightheaded when standing, or notice a significant drop in urination, seek immediate emergency medical care rather than managing this at home.

The throughline across all of these strategies is communication. A dose pause, a dose reduction, or a slower titration schedule are all preferable to stopping the medication abruptly, and your prescriber can only make that call with accurate information about what you’re experiencing and when. Our guide to the Wegovy dosing schedule covers how a clinician-supervised titration plan is typically structured.

Dose Escalation: Why the Early Weeks Matter Most

Wegovy’s side-effect profile is closely tied to dose level, which is exactly why the standard prescribing approach starts low and increases gradually rather than beginning at the target maintenance dose. Each step up raises gastrointestinal exposure, and a measurable share of adverse events appear or intensify in the days following a dose increase before settling back down.

The core principles behind flexible titration are straightforward:

  • Start at the lowest dose and increase on a schedule rather than jumping to a higher dose quickly.
  • Pause at the current dose if symptoms become moderate to severe rather than pushing through to the next increase on schedule.
  • Drop back to the last well-tolerated dose if a higher dose produces symptoms that don’t improve within a reasonable window.
  • Accept a maintenance dose below the standard label maximum when that’s what the individual tolerates well, since effective treatment doesn’t require everyone to reach the same ceiling.

Evidence backing this approach shows that a slower escalation pace reduces nausea and discontinuation rates without reducing overall weight-loss efficacy, according to research on GLP-1 tolerability. That’s a meaningful finding because it means tolerability and results aren’t in tension with each other: moving slower doesn’t cost you effectiveness. Our semaglutide dose escalation guide walks through how these adjustments typically work in practice.

Drug Interactions and Precautions Before Procedures

A handful of interactions and situational precautions are worth flagging to anyone starting Wegovy, particularly people managing diabetes or facing an upcoming procedure.

  • Taking insulin or sulfonylureas alongside Wegovy raises the risk of hypoglycemia, so glucose monitoring and a possible dose reduction of those medications are commonly recommended.
  • Tell your surgical or anesthesia team that you’re taking Wegovy before any procedure involving general anesthesia or deep sedation, since GLP-1 medications have been associated with pulmonary aspiration risk during these procedures, according to perioperative safety guidance.
  • If severe vomiting or diarrhea causes significant fluid loss, kidney function monitoring becomes important, especially for people with existing kidney impairment.
  • People with a history of diabetic retinopathy may need closer eye monitoring, since some trial participants with pre-existing retinopathy experienced complications.

These precautions aren’t reasons for alarm, they’re information your care team needs to manage your treatment safely around other aspects of your health. Our GLP-1 medication safety information page covers monitoring and interaction guidance in more depth.

Special Populations: Who Needs Closer Monitoring

Certain groups face different risk profiles on Wegovy and benefit from more tailored monitoring conversations with their prescriber.

  • People with type 2 diabetes need closer glucose monitoring, since hypoglycemia incidents were more frequent in trial participants also managing diabetes with other medications.
  • Adolescents show higher cholelithiasis (gallstone) rates in pediatric trial data, which factors into prescribing caution for younger patients.
  • Older adults may show fracture and orthostatic hypotension (a drop in blood pressure on standing) signals in some trial populations, making careful monitoring worthwhile.
  • People with renal impairment or a personal or family history of thyroid disease need additional screening, since kidney function and thyroid history both affect whether and how Wegovy should be used.

None of these factors automatically rule someone out from treatment, but they shape how closely a prescriber monitors you and how often follow-up visits happen.

Red Flags That Mean You Should Stop and Seek Care

Certain symptoms cross the line from “normal adjustment” to “needs immediate attention.” Knowing the list ahead of time means you won’t have to figure it out while you’re not feeling well.

  1. Severe or persistent upper abdominal pain, especially if it radiates to your back, which can signal pancreatitis.
  2. Yellowing of the skin or eyes, dark urine, or pale stools, which can point to gallbladder disease.
  3. Signs of severe hypoglycemia, including confusion, shakiness, sweating, or loss of consciousness.
  4. Swelling of the face, lips, tongue, or throat, or difficulty breathing, which can indicate a severe allergic reaction.
  5. Fainting or signs of severe dehydration from ongoing vomiting or diarrhea.

If you notice any of these, stop the medication, seek emergency care, and notify your prescribing clinician as soon as possible. It helps to document when the symptom started relative to your last dose, since that timing informs whether treatment resumes, pauses, or stops. You or your prescriber can also report suspected adverse events to the FDA’s MedWatch program. Keeping a simple record of dates, doses, and symptom onset makes these conversations faster and more useful for everyone involved.

Why Tolerability and Treatment Success Go Together

Gastrointestinal side effects get a lot of attention, and they should, but they’re also the part of Wegovy treatment that responds best to a thoughtful approach. These symptoms are dose-related and largely transient, and a flexible titration schedule that respects how an individual body responds tends to preserve the medication’s effectiveness while making the experience more livable.

Permanent discontinuation due to side effects is uncommon in trial data, which tells me most people who have a rough week or two during a dose increase go on to find a maintenance dose that works for them. The patients who do best tend to be the ones who stay in close contact with their prescriber rather than toughing out symptoms alone or quitting at the first sign of trouble. A documented titration plan, adjusted in real time based on what you’re actually experiencing, beats a rigid one-size-fits-all schedule every time.

— Bryan

How We Help You Tolerate Wegovy and Find Your Right Dose

Clinician-supervised titration is at the center of how we handle GLP-1 treatment, including Wegovy dosing support, because the pace of dose increases matters as much as the medication itself. Every plan includes free provider visits and unlimited coaching, so if nausea or another side effect shows up, you can get support.

Legacymeds

  • Individualized titration schedules built around how your body responds, not a fixed calendar.
  • Unlimited support between visits so a rough week doesn’t turn into an unnecessary discontinuation.
  • No membership fees or insurance requirements to start a clinician-guided program.

If you’re weighing Wegovy or already on it and want a program built around your tolerability, explore our GLP-1 injections, tablets, and Wegovy options and request a clinician assessment to get started.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What are the most common Wegovy side effects?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation, affecting roughly 44%, 30%, 25%, and 24% of patients respectively in clinical trials. Headache, fatigue, dyspepsia, and dizziness are also reported in a meaningful share of patients.

How long do Wegovy side effects typically last?

Most gastrointestinal episodes are short: nausea has a median duration of about 8 days, diarrhea about 3 days, and vomiting about 2 days per episode, according to trial data summaries. Symptoms tend to peak during dose escalation and ease as the body adjusts to each new dose.

What side effects of Wegovy require emergency care?

Severe or persistent upper abdominal pain, yellowing skin or eyes, signs of severe low blood sugar, and swelling or breathing difficulty from a severe allergic reaction all require immediate medical attention. These can signal pancreatitis, gallbladder disease, dangerous hypoglycemia, or anaphylaxis, all of which are listed as warnings in the prescribing information.

Can slower dose titration reduce Wegovy side effects?

Yes, a slower, more flexible titration schedule has been shown to reduce nausea and discontinuation rates without reducing overall weight-loss results, according to research on GLP-1 tolerability management. Working with a prescriber to pause or reduce a dose when symptoms are hard to tolerate is a standard part of this approach.

Does Wegovy increase the risk of gallbladder problems?

Yes, cholelithiasis, or gallstones, was reported in about 1.6% of injection-treated adults compared with 0.7% on placebo in clinical review data. Rapid or substantial weight loss independently raises gallstone risk as well, regardless of the method used to achieve it.

Sources

Ready to start your weight loss journey?

Doctor-led GLP-1 plans starting at $148/mo with free shipping.

Get Approved